Wiltrom Co Ltd

Wiltrom's capital structure is characterized by a low debt-to-equity ratio of 0.14, indicating a conservative leverage profile, and a strong current ratio of 8.57, suggesting robust short-term liquidity. The company holds TWD 91.8 million in cash and equivalents, which is 12.9% of total assets, and has no immediate dilution or liquidity flags. Profitability metrics show a challenging performance, with a negative return on equity (ROE) of -3.34% and a return on assets (ROA) of -2.69%. These figures fall below the typical industry benchmarks for medical equipment firms, which usually maintain ROE above 10% and ROA above 5%. The company reported a net loss of TWD 19.1 million and an operating loss of TWD 28.4 million, reflecting operational inefficiencies or declining margins. The company's revenue is concentrated in three primary product lines: spinal fusion surgery products, spinal compression fracture surgery products, and bone cement products. While the geographic distribution spans Taiwan, Asia, and America, the input data does not specify the exact revenue contribution by region, limiting visibility into geographic concentration risk. Looking ahead, the company's revenue outlook is uncertain. The current fiscal year (FY) is expected to show a decline, with no clear indication of recovery in the next FY. The operating cash flow of TWD -4.7 million and free cash flow of TWD -8.0 million suggest ongoing cash burn, which could pressure future operations if not reversed. Risk factors include the company's negative net income and operating income, which may signal underlying operational or market challenges. The absence of immediate dilution or liquidity flags is a positive, but the negative cash flows and low profitability remain key concerns. No dilution sources were identified in the latest filings, and the company has not issued shares recently, suggesting no near-term dilution pressure. Recent events, as per the latest financial snapshot, include a net loss and operating loss, with no disclosed material events or regulatory actions. The company's capital expenditure of TWD -10.0 million indicates ongoing investment in operations, but the negative cash flows suggest these investments are not yet generating returns.